CSL acquired Novartis's business for $275 million
Novartis has announced that it has completed the divestiture of its influenza vaccine unit to CSL Limited. This marks the end of a series of transactions previously announced and completed, that are focusing Novartis on its three leading businesses of global scale - pharmaceuticals, generics and eye care.
Since April 2014, the influenza vaccines unit results have been reported under Discontinuing Operations in the Novartis consolidated financial statements.
Australia's CSL, the world's largest blood products company, has acquired Novartis AG's global influenza vaccine business for $275 million.